Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting

Annals of Pharmacotherapy

Volumn 38, Issue 7-8, 2004, Pages 1301-1306

  Morera, Tomas ^a   Gervasini, Guillermo ^b   Carrillo, Juan A ^b   Benitez, Julio ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Drug Survlnc Centre of Extremadura   (Spain)

Author keywords

Azole antifungals; Computerized prescription handling; Drug interaction; Rhabdomyolysis; Statins

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; PRAVASTATIN; PYRROLE DERIVATIVE; SIMVASTATIN;

ADULT; AGED; ARTICLE; COMPUTER SYSTEM; CONSUMER; DRUG SAFETY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MALE; OUTPATIENT DEPARTMENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; RURAL AREA; SCREENING; SIDE EFFECT; SPAIN;

ANTIFUNGAL AGENTS; AZOLES; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 3042554542     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D549     Document Type: Article

References (35)

1. Hamilton RA, Briceland LL, Andritz MH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 1998;18:1112-20.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
3. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990;228:83-90.
4. Colt HG, Shapiro AP. Drug-induced illness as a cause for admission to a community hospital. J Am Geriatr Soc 1989;37:323-6.
5. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 2001;31:199-205.
6. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6. DOI 10.1345/aph.1A333
7. Tamblyn R, Huang A, Perreault R, Jacques A, Roy D, Hanley J, et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ 2003;169:549-56.
8. Hanlon JT, Schmader KE, Ruby CM, Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001;49:200-9.
9. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000;169:176-9.
10. Bates DW, Pappius E, Kuperman GJ, Sittig D, Burstin H, Fairchild D, et al. Using information systems to measure and improve quality. Int J Med Inf 1999;53:115-24.
11. Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999;6:313-21.
12. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA, et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84.
13. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274:29-34.
14. Rosholm JU, Bjermm L, Hallas J, Worm J, Gram LF. Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull 1998;45:210-3.
15. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998;12:485-94.
16. Halkin H, Katzir I, Kurman I, Jan J, Malkin BB. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001;69:260-5.
17. Bottorff M. "Fire and forget?" Pharmacological considerations in coronary care. Atherosclerosis 1999;147(suppl 1):S23-30.
18. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999;27:173-9.
19. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998;64:477-83.
20. Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm 1998;55:2253-67.
21. Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996;277:321-32.
22. Gibbs MA, Kunze KL, Howald WN, Thummel KE. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 1999;27:596-9.
23. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6.
24. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003;37:1032-5. DOI 10.1345/aph.1C467
25. Vlahakos DV, Manginas A, Chilidou D, Zamanika C, Alivizatos PA. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation 2002;73:1962-4.
26. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95. DOI 10.1345/aph.1A289
27. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107. DOI 10.1345/aph.10228
28. Guedon-Moreau L, Ducrocq D, Duc MF, Quieureux Y, L'Hote C, Deligne J, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003;59:689-95.
29. Martin I, Hall J, Gardner T. Prescribing for patients aged 65 years and over in New Zealand general practice. N Z Med J 2002;115:U221.
30. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther 2002;27:377-82.
31. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002;40:1161-71.
32. Isaksen SF, Jonassen J, Malone DC, Billups SJ, Carter BL, Sintek CD. Estimating risk factors for patients with potential drug-related problems using electronic pharmacy data. IMPROVE investigators. Ann Pharmacother 1999;33:406-12. DOI 10.1345/aph.18268
33. Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-5.
34. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Lopez-Lirola A, Rodriguez-Rodriguez E, Santolaria-Fernandez F. Acute rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med 2001;161:893.
35. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001;175:486-9.